

Morningstar[®] Document ResearchSM

FORM 8-K

Shire plc - N/A

Filed: May 03, 2016 (period: May 03, 2016)

Report of unscheduled material events or corporate changes.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 3, 2016

Shire plc

(Exact name of registrant as specified in its charter)
Jersey, Channel Islands

(State or other jurisdiction of incorporation)

0-29630
(Commission File Number)

98-0601486
(IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin
24, Republic of Ireland

(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code +353 1 429 7700

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events

Shire plc have issued the press releases attached hereto as Exhibits 99.1 and 99.2 which are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits. The following exhibits are filed herewith:

99.1 Press Release dated May 3, 2016

99.2 Press Release dated May 3, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC

By: /s/ W R Mordan

Name: Bill Mordan

Title: Company Secretary

Dated: May 3, 2016

Press Release

www.shire.com



Director/PDMR Shareholding

May 3, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces it was notified on May 2, 2016, that on that date, Performance Share Awards ("PSAs") granted to Flemming Ornskov, Chief Executive Officer of the Company, vested. The PSAs were granted under Part B of the Shire Portfolio Share Plan ("PSP") on May 2, 2013, and formed part of a replacement equity award granted to Dr. Ornskov following his initial appointment. The number of American Depositary Shares ("ADSs") released and the number sold were as follows:

ADSs released ⁽¹⁾⁽²⁾	ADSs sold ⁽³⁾
10,942	3,111

- (1) In accordance with the rules of the PSP, upon vesting the PSAs were increased by an amount equivalent to the value of dividends paid by the Company in respect of the PSAs from the date of grant to the date of vesting.
- (2) The number of ADSs released reflects the vesting of PSAs which were subject to performance conditions measured over the period from January 1, 2013, to December 31, 2015. Based on these conditions, 100% of the PSAs vested.
- (3) ADSs were sold to satisfy personal tax liabilities. The sale of ADSs took place on the NASDAQ Global Select Market at an average price of \$186.5008 per ADS.

The Company further announces it was notified on May 2, 2016, that on that date, deferred ADSs granted to Mark Enyedy, a Person Discharging Managerial Responsibilities, were automatically released. The deferred ADSs were granted under the terms of a deferred share award which vested on May 1, 2016. The number of ADSs released and the number that lapsed were as follows:

ADSs released ⁽⁴⁾	ADSs lapsed ⁽⁵⁾
493	238

- (4) In accordance with the terms of the deferred share award, upon release the deferred ADSs were increased by an amount equivalent to the value of dividends paid by the Company in respect of the deferred ADSs from the date of grant to the date of vesting.
- (5) The ADSs that lapsed were equivalent in value to Mr. Enyedy's tax liability resulting from the release of the deferred ADSs.

One ADS is equal to three Ordinary Shares of 5 pence each in the Company. No amount was payable by Dr. Ornskov or Mr. Enyedy upon vesting of their awards.

This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.

Oliver Strawbridge
Senior Assistant Company Secretary

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

For further information please contact:

Investor Relations

Sarah Elton-Farr

seltonfarr@shire.com

+44 1256 894157

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com

Press Release

www.shire.com



Total Voting Rights

May 3, 2016 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority's (the "FCA") Disclosure Rules and Transparency Rules, notifies the market of the following:

As at April 30, 2016, the Company's issued ordinary share capital comprised 593,256,106 ordinary shares of 5 pence each with voting rights and a further 7,971,461 ordinary shares held in treasury.

Therefore the total number of voting rights in the Company is 593,256,106. This is the figure which should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Rules and Transparency Rules.

Sarah Howfield
Assistant Company Secretary

For further information please contact:

Investor Relations

Sarah Elton-Farr

seltonfarr@shire.com

+44 1256 894157

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.

www.shire.com

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX